l 778,123 has been researched along with epidermal growth factor in 1 studies
| Studies (l 778,123) | Trials (l 778,123) | Recent Studies (post-2010) (l 778,123) | Studies (epidermal growth factor) | Trials (epidermal growth factor) | Recent Studies (post-2010) (epidermal growth factor) |
|---|---|---|---|---|---|
| 23 | 3 | 2 | 24,155 | 217 | 4,699 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barber, PR; Cornelissen, B; Darbar, S; Hernandez, R; Kersemans, V; Reilly, R; Smart, S; Tullis, I; Vallis, KA; Vojnovic, B | 1 |
1 other study(ies) available for l 778,123 and epidermal growth factor
| Article | Year |
|---|---|
ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
Topics: Active Transport, Cell Nucleus; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Colony-Forming Units Assay; Dimethylallyltranstransferase; Electrons; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Imidazoles; Mice; Pentetic Acid; Protein Kinase Inhibitors; Protein Transport; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |